Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2007 Nov 15;110(10):3561-3. Epub 2007 Aug 2.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Author information

1
Stem Cell Transplantation Program of the Section of Hematology-Oncology, Boston University School of Medicine, Boston, MA 02118, USA. vaishali.sanchorawala@bmc.org

Abstract

Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.

PMID:
17673601
PMCID:
PMC2077307
DOI:
10.1182/blood-2007-07-099481
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center